Cue Biopharma (CUE) vs Pliant Therapeutics (PLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pliant Therapeutics (PLRX) has outperformed Cue Biopharma (CUE) over the past year, losing 61.6% versus a loss of 76.8%. Over five years, PLRX leads with a -95.9% price change compared with -98.9% for CUE. Pliant Therapeutics is the larger company by market cap ($36.9 million vs $34.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | PLRX |
|---|---|---|
| Share price | $4.15 | $0.5951 |
| Market cap | $34.69M | $36.89M |
| 1-day change | -7.78% | -4.02% |
| YTD return | -54.64% | -51.22% |
| 1-year return | -76.75% | -61.61% |
| 5-year return | -98.92% | -95.89% |
| EPS (TTM) | $-27.80 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.47M | $0 |
| Revenue growth (YoY) | +195.75% | — |
| Net income (latest FY) | $-26.60M | $-149.34M |
| Operating margin | -96.67% | — |
| Net margin | -96.85% | — |
| 52-week high | $45.50 | $1.67 |
| 52-week low | $2.83 | $0.5719 |
| Distance from 52-week high | -90.88% | -64.37% |
| Analyst consensus | none | none |
| Avg. price target upside | +2020.48% | +236.08% |
| Average volume | 567.02K | 408.93K |
| Shares outstanding | 8.36M | 61.99M |
| Employees | 29 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRX has outperformed CUE by 15.1 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
CUE vs PLRX FAQ
Which is bigger, Cue Biopharma or Pliant Therapeutics?
Pliant Therapeutics (PLRX) is larger, with a market capitalization of $36.89M compared with $34.69M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or PLRX?
PLRX returned -61.61% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Pliant Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.